Steve Gentleman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5808631/publications.pdf

Version: 2024-02-01

84 papers 7,947 citations

40 h-index 72 g-index

89 all docs 89 docs citations

89 times ranked 9900 citing authors

#	Article	IF	CITATIONS
1	Inflammation after trauma: Microglial activation and traumatic brain injury. Annals of Neurology, 2011, 70, 374-383.	2.8	803
2	Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain, 2011, 134, 2755-2771.	3.7	685
3	Evidence for α-synuclein prions causing multiple system atrophy in humans with parkinsonism. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E5308-17.	3.3	578
4	\hat{l}^2 -Amyloid precursor protein (\hat{l}^2 APP) as a marker for axonal injury after head injury. Neuroscience Letters, 1993, 160, 139-144.	1.0	545
5	Transmission of multiple system atrophy prions to transgenic mice. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 19555-19560.	3.3	359
6	Microglial Activation in Traumatic Brain Injury. Frontiers in Aging Neuroscience, 2017, 9, 208.	1.7	307
7	Nucleus basalis of Meynert revisited: anatomy, history and differential involvement in Alzheimer's and Parkinson's disease. Acta Neuropathologica, 2015, 129, 527-540.	3.9	255
8	Axonal injury: a universal consequence of fatal closed head injury?. Acta Neuropathologica, 1995, 89, 537-543.	3.9	252
9	Long-term intracerebral inflammatory response after traumatic brain injury. Forensic Science International, 2004, 146, 97-104.	1.3	228
10	Markers of axonal injury in post mortem human brain. Acta Neuropathologica, 1994, 88, 433-439.	3.9	209
11	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nature Genetics, 2021, 53, 294-303.	9.4	198
12	Propagation of prions causing synucleinopathies in cultured cells. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E4949-58.	3.3	191
13	The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson's disease: a critical analysis of αâ€synuclein staging. Neuropathology and Applied Neurobiology, 2008, 34, 284-295.	1.8	186
14	Is \hat{I}^2 -APP a marker of axonal damage in short-surviving head injury?. Acta Neuropathologica, 1996, 92, 608-613.	3.9	178
15	The neuroinflammatory response in humans after traumatic brain injury. Neuropathology and Applied Neurobiology, 2013, 39, 654-666.	1.8	154
16	The structural differences between patient-derived α-synuclein strains dictate characteristics of Parkinson's disease, multiple system atrophy and dementia with Lewy bodies. Acta Neuropathologica, 2020, 139, 977-1000.	3.9	149
17	Glycogen Synthase Kinase 3 Inhibition Promotes Lysosomal Biogenesis and Autophagic Degradation of the Amyloid- \hat{l}^2 Precursor Protein. Molecular and Cellular Biology, 2012, 32, 4410-4418.	1.1	147
18	Cognitive decline following major surgery is associated with gliosis, \hat{l}^2 -amyloid accumulation, and \ddot{l} , phosphorylation in old mice. Critical Care Medicine, 2010, 38, 2190-2198.	0.4	146

#	Article	IF	Citations
19	Parkinson's disease is associated with altered expression of CaV1 channels and calcium-binding proteins. Brain, 2013, 136, 2077-2097.	3.7	144
20	Dementia and visual hallucinations associated with limbic pathology in Parkinson's disease. Parkinsonism and Related Disorders, 2009, 15, 196-204.	1.1	114
21	Neuropathological consensus criteria for the evaluation of Lewy pathology in post-mortem brains: a multi-centre study. Acta Neuropathologica, 2021, 141, 159-172.	3.9	107
22	A \hat{l}^242 is the predominant form of amyloid b -protein in the brains of short-term survivors of head injury. NeuroReport, 1997, 8, 1519-1522.	0.6	98
23	Next generation histology methods for three-dimensional imaging of fresh and archival human brain tissues. Nature Communications, 2018, 9, 1066.	5.8	98
24	Chapter 16 Molecular pathology of head trauma: altered \hat{l}^2 APP metabolism and the aetiology of Alzheimer's disease. Progress in Brain Research, 1993, 96, 237-246.	0.9	82
25	Neuropathology of dementia in patients with Parkinsonâ \in ^M s disease: a systematic review of autopsy studies. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, jnnp-2019-321111.	0.9	80
26	Diverse human astrocyte and microglial transcriptional responses to Alzheimer's pathology. Acta Neuropathologica, 2022, 143, 75-91.	3.9	80
27	\hat{l}^2 -Amyloid (A \hat{l}^2)42(43), A \hat{l}^2 42, A \hat{l}^2 40 and apoE immunostaining of plaques in fatal head injury. Neuropathology and Applied Neurobiology, 2000, 26, 124-132.	1.8	77
28	MSA prions exhibit remarkable stability and resistance to inactivation. Acta Neuropathologica, 2018, 135, 49-63.	3.9	70
29	Cortical Lewy bodies and $\hat{A^2}$ burden are associated with prevalence and timing of dementia in Lewy body diseases. Neuropathology and Applied Neurobiology, 2016, 42, 436-450.	1.8	67
30	Striatal \hat{A}^2 peptide deposition mirrors dementia and differentiates DLB and PDD from other Parkinsonian syndromes. Neurobiology of Disease, 2011, 41, 377-384.	2.1	66
31	Disturbed sleep in <scp>P</scp> arkinson's disease: anatomical and pathological correlates. Neuropathology and Applied Neurobiology, 2013, 39, 644-653.	1.8	63
32	Somatic copy number gains of α-synuclein (SNCA) in Parkinson's disease and multiple system atrophy brains. Brain, 2018, 141, 2419-2431.	3.7	63
33	Bringing <scp>CLARITY</scp> to the human brain: visualization of Lewy pathology in three dimensions. Neuropathology and Applied Neurobiology, 2016, 42, 573-587.	1.8	62
34	Genetic determinants of survival in progressive supranuclear palsy: a genome-wide association study. Lancet Neurology, The, 2021, 20, 107-116.	4.9	62
35	Multiple system atrophy prions retain strain specificity after serial propagation in two different Tg(SNCA*A53T) mouse lines. Acta Neuropathologica, 2019, 137, 437-454.	3.9	58
36	Markers of axonal injury in post mortem human brain. Acta Neuropathologica, 1994, 88, 433-439.	3.9	50

3

#	Article	IF	Citations
37	Axonal Injury Is Accentuated in the Caudal Corpus Callosum of Head-Injured Patients. Journal of Neurotrauma, 2001, 18, 1-9.	1.7	48
38	Primum non nocere: a call for balance when reporting on CTE. Lancet Neurology, The, 2019, 18, 231-233.	4.9	48
39	From biomechanics to pathology: predicting axonal injury from patterns of strain after traumatic brain injury. Brain, 2021, 144, 70-91.	3.7	47
40	<i>LRRK2</i> exonic variants and risk of multiple system atrophy. Neurology, 2014, 83, 2256-2261.	1.5	46
41	Chemical Probes for Visualizing Intact Animal and Human Brain Tissue. Cell Chemical Biology, 2017, 24, 659-672.	2.5	45
42	\hat{l}_{\pm} -synuclein induced synapse damage is enhanced by amyloid- \hat{l}^21 -42. Molecular Neurodegeneration, 2010, 5, 55.	4.4	43
43	Clinical correlates of pathology in the claustrum in Parkinson's disease and dementia with Lewy bodies. Neuroscience Letters, 2009, 461, 12-15.	1.0	42
44	Variation at the <i>TRIM11</i> locus modifies progressive supranuclear palsy phenotype. Annals of Neurology, 2018, 84, 485-496.	2.8	37
45	Free of acrylamide sodium dodecyl sulphate (SDS)â€based tissue clearing (FASTClear): a novel protocol of tissue clearing for threeâ€dimensional visualization of human brainÂtissues. Neuropathology and Applied Neurobiology, 2017, 43, 346-351.	1.8	36
46	Investigation of somatic CNVs in brains of synucleinopathy cases using targeted SNCA analysis and single cell sequencing. Acta Neuropathologica Communications, 2019, 7, 219.	2.4	35
47	Neuropathological changes in the nucleus basalis in schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 485-495.	1.8	32
48	Rationalisation and Validation of an Acrylamide-Free Procedure in Three-Dimensional Histological Imaging. PLoS ONE, 2016, 11, e0158628.	1.1	32
49	ARTAG in the basal forebrain: widening the constellation of astrocytic tau pathology. Acta Neuropathologica Communications, 2016, 4, 59.	2.4	31
50	Review: Microglia in protein aggregation disorders: friend or foe?. Neuropathology and Applied Neurobiology, 2013, 39, 45-50.	1.8	30
51	Axonal injury: a universal consequence of fatal closed head injury?. Acta Neuropathologica, 1995, 89, 537-543.	3.9	30
52	The aftermath of boxing revisited: identifying chronic traumatic encephalopathy pathology in the original Corsellis boxer series. Acta Neuropathologica, 2018, 136, 973-974.	3.9	28
53	Prion protein immunocytochemistryUK five centre consensus report. Neuropathology and Applied Neurobiology, 1997, 23, 26-35.	1.8	28
54	Cross-platform transcriptional profiling identifies common and distinct molecular pathologies in Lewy body diseases. Acta Neuropathologica, 2021, 142, 449-474.	3.9	27

#	Article	IF	CITATIONS
55	Celastrol Enhances Cell Viability and Inhibits Amyloid-β Production Induced by Lipopolysaccharide In Vitro. Journal of Alzheimer's Disease, 2014, 41, 835-844.	1.2	25
56	Review: Revisiting the human cholinergic nucleus of the diagonal band of Broca. Neuropathology and Applied Neurobiology, 2018, 44, 647-662.	1.8	25
57	Parametric mapping using spectral analysis for 11C-PBR28 PET reveals neuroinflammation in mild cognitive impairment subjects. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1432-1441.	3.3	22
58	Iron and inflammation: in vivo and post-mortem studies in Parkinson's disease. Journal of Neural Transmission, 2021, 128, 15-25.	1.4	22
59	Altered Expression of Brain Proteinase-Activated Receptor-2, Trypsin-2 and Serpin Proteinase Inhibitors in Parkinson's Disease. Journal of Molecular Neuroscience, 2015, 57, 48-62.	1.1	19
60	Evidence against a reliable staging system of αâ€synuclein pathology in Parkinson's disease. Neuropathology and Applied Neurobiology, 2009, 35, 125-126.	1.8	17
61	Calcium CaV1 Channel Subtype mRNA Expression in Parkinson's Disease Examined by In Situ Hybridization. Journal of Molecular Neuroscience, 2015, 55, 715-724.	1.1	17
62	Genetic evaluation of dementia with Lewy bodies implicates distinct disease subgroups. Brain, 2022, 145, 1757-1762.	3.7	17
63	Cholinergic deficits and galaninergic hyperinnervation of the nucleus basalis of Meynert in Alzheimer's disease and Lewy body disorders. Neuropathology and Applied Neurobiology, 2020, 46, 264-278.	1.8	16
64	Multisystem screening reveals <scp>SARSâ€CoV</scp> â€2 in neurons of the myenteric plexus and in megakaryocytes. Journal of Pathology, 2022, 257, 198-217.	2.1	16
65	Faster disease progression in Parkinson's disease with type 2 diabetes is not associated with increased αâ€synuclein, tau, amyloidâ€Î² or vascular pathology. Neuropathology and Applied Neurobiology, 2021, 47, 1080-1091.	1.8	14
66	Differential expression of galanin in the cholinergic basal forebrain of patients with Lewy body disorders. Acta Neuropathologica Communications, 2015, 3, 77.	2.4	13
67	LRP10 in α-synucleinopathies. Lancet Neurology, The, 2018, 17, 1033-1034.	4.9	11
68	The Levodopa Response Varies in Pathologically Confirmed Parkinson's Disease: A Systematic Review. Movement Disorders Clinical Practice, 2020, 7, 218-222.	0.8	9
69	A novel method to visualise the threeâ€dimensional organisation of the human cerebral cortical vasculature. Journal of Anatomy, 2018, 232, 1025-1030.	0.9	8
70	Differential effects of amyloid-beta peptide aggregation status on in vivo retinal neurotoxicity. Eye and Brain, 2010, 2, 121.	3.8	4
71	The diagonal band of Broca in health and disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2021, 179, 175-187.	1.0	4
72	Methods for next generation three-dimensional histology for human neural tissues. Protocol Exchange, 0 , , .	0.3	1

#	Article	IF	CITATIONS
73	Examination of glial and neuronal changes in the nucleus basalis of Meynert in schizophrenia and recurrent depression. International Clinical Psychopharmacology, 2011, 26, e126.	0.9	O
74	[P1â€"123]: STRATEGIES TO DEVELOP PARAMETRIC MAPS FOR TSPO PET TRACER [11C]â€PBR28 IN PATIENTS W MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P288.	TH.4	0
75	[P1â€"124]: REGIONAL KINETIC MODELLING APPLICATION FOR TSPO PET TRACER [11C]PBR28. Alzheimer's and Dementia, 2017, 13, P289.	0.4	O
76	[O3–09–06]: MICROGLIAL ACTIVATION IN ALZHEIMER'S DISEASE DETECTED BY NOVEL THIRD GENERATION TRANSLOCATOR PROTEIN TRACER FLUTRICICLAMIDE ([18F]GE180). Alzheimer's and Dementia, 2017, 13, P922.	0.4	0
77	[S1–02–03]: LINKING TRAUMATIC BRAIN INJURY TO NEURODEGENERATIVE DISEASE. Alzheimer's and Dementia, 2017, 13, P170.	0.4	O
78	P1â€475: NOVEL THIRD GENERATION MICROGLIAL MARKER FLUTRICICLAMIDE ([18F]GE180) IN ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2018, 14, P506.	0.4	0
79	TauBI or not TauBI: what was the question?. Brain, 2018, 141, 2536-2539.	3.7	O
80	Microglial activation evaluated using flutriciclamide (11 Fâ€GE180) in subjects with cognitive impairment. Alzheimer's and Dementia, 2020, 16, e045465.	0.4	0
81	Tau formation is associated with microglial activation in more widespread cortical areas than is amyloid deposition. Alzheimer's and Dementia, 2020, 16, e046045.	0.4	O
82	Neuropathological Assessment as an Endpoint in Clinical Trial Design. Methods in Molecular Biology, 2018, 1750, 271-279.	0.4	0
83	Influence of microglial activation on structural and functional connectivity in mild cognitive impairment subjects. Alzheimer's and Dementia, 2020, 16, e042990.	0.4	O
84	Somatic copy number variant mutations in alpha-synuclein and genome-wide in brains of synucleinopathy cases. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A4.2-A4.	0.9	0